Seattle-based vaccines developer Icosavax has secured $52 million in Series A funding. Qiming Venture Partners USA led the round with participation from Adams Street Partners, Sanofi Ventures and NanoDimension.
Source: Press Release
Vaccines developer Icosavax procures $52 mln Series A
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.